Elevance Health Inc.

Elevance Health Inc.

ELV

$413.75

Updated: 03/11/2026, 23:28:59

Market Cap
$89.73B
Sector
Healthcare
Industry
Medical - Healthcare Plans
Country
US

No historical data available

Company Profile

Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. It facilitates access to vital care, assistance, and tools designed to enable healthier living for approximately 118 million individuals. The company's comprehensive offerings span medical, digital, pharmaceutical, behavioral health, clinical, and other care solutions. Founded in 1944 and based in Indianapolis, Indiana, this entity adopted its current name, Elevance Health Inc., in June 2022, having previously operated as Anthem, Inc.

USD
NYSE
CEO: Gail Koziara Boudreaux
Employees: 96,615
https://www.elevancehealth.com
Asset Summaries
Latest generated summaries for ELV

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
ELV-10-k-fy2025.html3.6 MBtext/htmlENFiled 06/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 49 KPI observations

Revenue

N/A

FY — · Reported

Net income

$5.7B

FY 2025 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

$3.2B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

$2.6B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

CarelonRx pharmacy services
Core go-to-market brands
Carelon Services whole-health services
Carelon Services
CarelonRx pharmacy services
Fee-based managed care services
Specialty products
Public Exchange participation
Other consumer brands

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Company overview

Health company serving full health journeys with medical, pharmacy, and behavioral health services

98%
Source evidence
“We support consumers throughout their full health journeys with medical, pharmacy, and behavioral health services designed to address their whole health needs.”

Company overview

One of the largest US health insurers; BCBSA independent licensee; CarelonRx pharmacy and Carelon Services businesses; licensed in all 50 states, DC and Puerto Rico.

98%
Source evidence
“We are one of the largest health insurers in the United States in terms of medical membership, serving approximately 45.2 million medical members through our affiliated health plans as of December 31, 2025.”

Geographic licensing footprint

Licensed insurance operations in all 50 states, DC and Puerto Rico

95%
Source evidence
“We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries.”

BCBSA affiliation and inter-plan arrangements

Independent BCBSA licensee; also conducts business through arrangements with other BCBS licensees and strategic partners

92%
Source evidence
“We are an independent licensee of the Blue Cross and Blue Shield Association ("BCBSA"), an association of independent health benefit plans.”

Corporate structure

Indiana corporation with direct and indirect subsidiaries

90%
Source evidence
“Elevance Health, Inc., an Indiana corporation, and, unless the context otherwise requires, its direct and indirect subsidiaries”

Reportable segments

Four reportable segments: Health Benefits, CarelonRx, Carelon Services, Corporate & Other

98%
Source evidence
“We report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other”

Reportable segments

Four reportable segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other

95%
Source evidence
“We report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other”

Named business lines: Carelon, CarelonRx, Commercial and Government Health Benefits

Executive leadership spans Carelon and CarelonRx, Commercial Health Benefits, and Government Health Benefits

85%
Source evidence
“Executive Vice President and President, Carelon and CarelonRx ... Executive Vice President and President, Commercial Health Benefits ... Executive Vice President and President, Government Health Benefits”

Markets served

Individual, Employer Group (risk-based and fee-based), Medicaid, Medicare, BlueCard, FEP members

97%
Source evidence
“offers a comprehensive suite of health plans and services to our Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid and FEP® members”

CarelonRx pharmacy services

Comprehensive pharmacy services: home delivery, specialty pharmacy, claims adjudication, formulary management, rebates, ambulatory infusion centers

97%
Source evidence
“CarelonRx offers a comprehensive portfolio of pharmacy services, which includes all core pharmacy services, such as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration”

Core go-to-market brands

Anthem BC/BCBS (Medicare, Medicaid, commercial plans), Wellpoint (Medicare, Medicaid, commercial), Carelon (CarelonRx and Carelon Services)

95%
Source evidence
“Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed Medicare, Medicaid, and commercial Health Benefit plans”

Carelon Services whole-health services

Carelon Services integrates physical, behavioral, pharmacy, social-care via Carelon Health and Carelon Insights

95%
Source evidence
“Our Carelon Services segment integrates physical, behavioral, pharmacy, and social-care capabilities to support whole-health services and enhance affordability for both internal and external customers”

Carelon Services

Healthcare related services offered as Carelon Services

95%
Source evidence
“other healthcare related services as Carelon Services”

CarelonRx pharmacy services

Pharmacy services offered through the CarelonRx business

95%
Source evidence
“we also offer pharmacy services through our CarelonRx business, and other healthcare related services as Carelon Services”

Fee-based managed care services

Broad array of managed care services to fee-based customers including claims processing, stop loss, network access, care management

95%
Source evidence
“we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, care provider network access, medical management, care management, wellness programs, actuarial services and other administrative services”

Specialty products

Specialty services include stop loss, dental, vision, supplemental health benefits; sold to affiliated and unaffiliated health plans

94%
Source evidence
“We provide an array of specialty services both to customers of our subsidiary health plans and to unaffiliated health plans, including pharmacy services, stop loss insurance, dental, vision and supplemental health insurance benefits”

Public Exchange participation

Participates in Public Exchange markets in many Medicaid states; rates set in spring for following year; expiration of enhanced PTCs at end of 2025 a risk factor

92%
Source evidence
“We participate in the Public Exchange in many of the states where we offer Medicaid health plans. The Public Exchange markets in general are highly volatile and unpredictable from year to year.”

Other consumer brands

Also serves members in numerous states as Wellpoint, Carelon, MMM and/or Simply Healthcare

90%
Source evidence
“we serve members in numerous states as Wellpoint, Carelon, MMM and/or Simply Healthcare”

Operations and dependencies

State revenue concentration

Largest revenue concentrations: California, New York, Virginia, Indiana, Ohio, Georgia, Florida and Texas

99%
Source evidence
“The states in which we operate with the largest concentrations of revenues include California, New York, Virginia, Indiana, Ohio, Georgia, Florida and Texas.”

Total workforce size and location split

Approximately 97,100 employees as of Dec 31, 2025; 71,900 in the US and 25,200 internationally; 99% full-time (at least 33 hours/week)

99%
Source evidence
“consisted of approximately 97,100 individuals, 71,900 in the United States and 25,200 internationally. Ninety-nine percent of our total workforce is employed full-time”

Positioning and strategy

Paragon Healthcare acquisition

CarelonRx acquired Paragon Healthcare (ambulatory infusion centers) in March 2024

95%
Source evidence
“ambulatory infusion centers, added to our portfolio in March 2024 through our acquisition of Paragon Healthcare, Inc. and its subsidiaries”

CareBridge acquisition

Acquired CareBridge at end of 2024 for virtual care to complex Medicaid/Medicare patients

94%
Source evidence
“we completed our acquisition of RSV QOZB LTSS, Inc. and certain affiliated entities (d/b/a CareBridge) at the end of 2024, which provides virtual care to complex Medicaid and Medicare patients”

Health Benefits segment key drivers

Health Benefits drivers: membership, health status, premium pricing, medical cost trend, network performance, risk adjustment, quality ratings, efficiency

95%
Source evidence
“Key drivers impacting the results of operations for our Health Benefits segment include membership levels and the health status of our members, premium pricing, medical cost trend, network performance, risk adjustment accuracy, quality ratings, and operating efficiency”

BCBSA licensee footprint

BCBS licensee in 14 state service areas; licensed for insurance operations in all 50 states, DC and Puerto Rico

97%
Source evidence
“We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries”

BCBS licensee service areas

Blue Cross licensee for California; BCBS licensee for 13 states with geographic exclusions; also serves members as Wellpoint, Carelon, MMM and/or Simply Healthcare

95%
Source evidence
“We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield ("BCBS") licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York”

Value-based care and care delivery integration

Value-based care product development and care delivery model integration are key to outcomes and cost management

85%
Source evidence
“if we are unable to provide higher quality outcomes and better experiences through the development and expansion of our value-based care products at lower costs or to integrate our care delivery model”

Risks, financing, and outlook

Rising healthcare cost drivers

Medical technology advances, drug utilization changes, demographics, regulation contribute to rising healthcare costs

93%
Source evidence
“Advances in medical technology, changes in prescription drug utilization, demographic trends and regulatory changes continue to contribute to rising healthcare costs.”

Substantial indebtedness and covenant risk

Substantial outstanding debt with interest-rate and covenant risk; default could make credit agreement obligations immediately due and payable

95%
Source evidence
“We have substantial indebtedness outstanding and may incur additional indebtedness in the future, which could adversely affect our ability to pursue desirable business opportunities”

International and FCPA regulatory exposure

International subsidiaries subject to varying jurisdictional requirements and U.S. laws including FCPA

90%
Source evidence
“our non-U.S. operations are subject to U.S. laws regulating the conduct and activities of U.S.-based businesses operating abroad, including but not limited to, the Foreign Corrupt Practices Act”

Guaranty fund assessment exposure

Subject to state guaranty fund assessments based on premiums written; future assessments likely

90%
Source evidence
“The amount and timing of any future assessments cannot be predicted with certainty; however, future assessments are likely to occur.”

Healthcare cost prediction and pricing risk

Profitability depends on predicting and pricing healthcare costs; numerous cost drivers could cause actual costs to exceed projections embedded in fixed 12-month commercial/Medicaid premiums and Medicare bids

98%
Source evidence
“If we fail to appropriately predict, price for and manage healthcare costs, the profitability of our products and services could decline”

Cybersecurity and data privacy risk

Cyber-attacks or privacy incidents at the company or third parties could cause data loss, disruption, litigation and regulatory penalties

98%
Source evidence
“A cyber-attack or other privacy or data security incident sustained by us or third parties we rely on could result in an unauthorized disclosure of sensitive or confidential information”

Pharmaceutical cost and regulatory risk

Pharmaceutical products and services are a significant component of healthcare costs; regulations, tariffs and discount changes may raise costs

95%
Source evidence
“Pharmaceutical products and services are a significant component of our healthcare costs.”

Enrollment reduction risk

Significant enrollment reduction in health benefits, pharmacy services or diversified products could adversely affect results, particularly in states with large regional concentrations

95%
Source evidence
“A significant reduction in the enrollment in our health benefits programs, pharmacy services or diversified products and services, particularly in states where we have large regional concentrations, could have an adverse effect”

Medicare bid and CMS margin requirements

Medicare revenue based on CMS bids submitted six months in advance with explicit gain/loss margin and MLR requirements; excess costs not recoverable in contract year

95%
Source evidence
“Our revenue from Medicare policies is based on bids submitted to CMS six months prior to the start of the contract year. CMS has explicit gain and loss margin requirements within the bids”

Public health crisis / pandemic risk

Pandemics and public health crises could raise medical costs, increase claims-estimation uncertainty, reduce enrollment and cause cash flow volatility

95%
Source evidence
“Increased estimation uncertainty for our claims liability, as well as decreased predictability of Medicare and Medicaid rates due to changes in utilization of medical facilities and services, medical expenses and other costs.”

AI-related regulatory and operational risk

Risks from responsible-AI compliance and emerging AI laws/standards could produce adverse outcomes for business, reputation and results

95%
Source evidence
“Any inadequacy in or failure to comply with our responsible use of AI policies and procedures or emerging laws, regulations and standards governing AI use could cause our technology not to operate as intended”

Holding company dependence on subsidiary dividends

As a holding company, dependent on dividends from regulated subsidiaries which are restricted by state insurance/HMO laws, RBC minimums and BCBSA capital requirements

95%
Source evidence
“As a holding company, we are dependent on dividends and administrative expense reimbursements from our subsidiaries. Among other restrictions, state insurance and HMO laws restrict the ability of most of our regulated subsidiaries to pay dividends.”

Premium rate pressure and regulatory rate restrictions

Pressure to contain premium rates from customers, competition, and federal/state regulators who may restrict or prevent rate changes

93%
Source evidence
“federal and state regulatory agencies may restrict or prevent entirely our ability to implement changes in premium rates.”

Key risks and uncertainties (forward-looking statement list)

Risks include cost trends, enrollment, Star Ratings, cyber, regulation, Caremark PSA non-compliance, debt, ratings downgrade, BCBSA license

92%
Source evidence
“risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicaid and Medicare Services Star Ratings”

Credit rating downgrade risk

Credit rating downgrades could restrict future borrowings, raise borrowing costs and impair competitive position

90%
Source evidence
“if our credit ratings are downgraded or placed under review, our business, cash flows, financial condition and results of operations could be adversely impacted by limitations on future borrowings and a potential increase in our borrowing costs”

Workforce talent competition and key executive succession

Intense competition for talent and key executive succession risk, including CEO succession

90%
Source evidence
“if we are unable to attract, retain and effectively manage the succession plans for key associates and executives, including our President and Chief Executive Officer, our business, results of operations and future performance could be adversely affected”

Guaranty association assessment exposure

State guaranty association assessments for impaired/insolvent insurers cannot currently be estimated but could adversely affect business

90%
Source evidence
“We are not currently able to estimate our potential financial obligations, losses or the availability of offsets associated with future guaranty association assessments”

Climate change and natural disaster exposure

Natural disasters and climate change could impact customers, associates, facilities and third-party vendors and the health benefits and pharmacy services industries

90%
Source evidence
“Natural disasters or extreme weather events, such as wildfires, floods, hurricanes, tropical storms, and snow and ice storms, have impacted, and may in the future impact, our customers, associates, facilities and third-party vendors”

Investment portfolio market risk

Significant investment portfolio subject to credit, liquidity, market and interest rate risks with potential impairment charges to income

90%
Source evidence
“We maintain a significant investment portfolio of cash equivalents and short-term and long-term investments in a variety of securities, which are subject to general credit, liquidity, market and interest rate risks.”

Material exposure graph

U.S. government agencies
Customer Exposure

Approximately 32% of 2025 consolidated revenues come from U.S. government agencies (CMS programs, FEP), mostly in Health Benefits segment

Relevance 95·Dependency 90·Confidence 97
Source evidence
“we generated approximately 32%, 31% and 29% of our total consolidated revenues from agencies of the U.S. government for the years ended December 31, 2025, 2024 and 2023, respectively”
Prescription drugs / pharmaceuticals
Cost Driver

Pharmaceutical prices, utilization, tariffs, DTC marketing by manufacturers, and changes in discounts are significant healthcare cost drivers.

Relevance 92·Dependency 78·Confidence 95
Source evidence
“increased number and cost of prescription drugs; direct-to-consumer marketing by drug manufacturers”
Medicare, Medicaid and commercial members
Revenue Exposure

Revenue is driven by membership across Medicare, Medicaid and commercial Health Benefit plans (~45.2 million medical members).

Relevance 90·Dependency 85·Confidence 92
Source evidence
“serving approximately 45.2 million medical members through our affiliated health plans as of December 31, 2025”
ACA / Medicare / Medicaid regulation
Regulatory Exposure

Changes to ACA, Medicare and Medicaid reimbursement, eligibility/redetermination, premium taxes and rate-setting directly affect ELV's premiums, fees and taxes and have adversely affected results.

Relevance 90·Dependency 85·Confidence 95
Source evidence
“changes in government regulations, policies or funding that apply to government-sponsored programs such as Medicare and Medicaid ... have adversely affected, and could in the future adversely affect, our business, cash flows, financial condition, and results of operations.”
CMS Medicare bid and MLR requirements
Regulatory Exposure

CMS gain/loss margin and contract-specific federal MLR requirements constrain recovery of costs exceeding projections in Medicare contracts.

Relevance 90·Dependency 82·Confidence 95
Source evidence
“CMS has explicit gain and loss margin requirements within the bids, as well as contract-specific federal MLR annual requirements.”
Medical cost trend
Cost Driver

Results depend on accurately predicting and managing healthcare costs via provider contracting, pricing, medical management; medical cost trend is a key Health Benefits driver

Relevance 90·Dependency 80·Confidence 92
Source evidence
“Our results of operations depend in large part on our ability to accurately predict and effectively manage healthcare costs through effective care provider contracting, product pricing, medical management and health and wellness programs”
CMS Star Ratings
Demand Driver

CMS Star Ratings performance influences Medicare Advantage reimbursements and eligibility for quality-based bonus payments

Relevance 90·Dependency 75·Confidence 94
Source evidence
“our performance under the Centers for Medicare & Medicaid Services (“CMS”) Star Ratings program, which influences Medicare Advantage plan reimbursements as well as our eligibility to earn quality-based bonus payments”
Medicaid eligibility redetermination
Demand Driver

More stringent Medicaid eligibility redetermination protocols by state agencies can reduce Medicaid membership and enrollment.

Relevance 88·Dependency 80·Confidence 92
Source evidence
“a reduction in Medicaid membership due to the implementation of more stringent eligibility redetermination protocols by state agencies”
Medicaid redeterminations
Demand Driver

Membership levels and mix change due to Medicaid redeterminations, aging population, utilization patterns and economic conditions

Relevance 85·Dependency 70·Confidence 90
Source evidence
“our results of operations are also impacted by membership levels and mix of membership, which has changed, and will continue to change, as a result of the pricing of our health benefits products and services, Medicaid redeterminations, an aging population, healthcare utilization patterns”
HIPAA / GDPR / CCPA-CPRA privacy and security laws
Legal Exposure

Evolving federal, state and international privacy/security laws create fines, penalties and litigation exposure around sensitive member data.

Relevance 85·Dependency 70·Confidence 95
Source evidence
“HIPAA's privacy and security rules, HIPAA's HITECH rule, the Gramm-Leach-Bliley Act, the General Data Protection Regulation and numerous state laws”
CarelonRx
Revenue Exposure

CarelonRx is a reportable segment selling pharmacy services to affiliated plans and external customers; key drivers include specialty drug trends and script volume

Relevance 85·Dependency 60·Confidence 90
Source evidence
“CarelonRx markets and offers pharmacy services to our affiliated health plan customers, as well as to external customers outside of the health plans we own.”
Blue Cross and Blue Shield Association license
Competitive Exposure

Company's brand and market access depend on BCBSA licenses; risk of events negatively affecting licenses disclosed

Relevance 80·Dependency 70·Confidence 88
Source evidence
“events that may negatively affect our licenses with the Blue Cross and Blue Shield Association”
Blue Cross and Blue Shield Association licensing
Regulatory Exposure

Company's go-to-market depends on BCBSA license rights in defined service areas, including geographic exclusions (e.g., 30 Kansas City-area counties in Missouri, Northern Virginia).

Relevance 75·Dependency 70·Confidence 90
Source evidence
“We are an independent licensee of the Blue Cross and Blue Shield Association ("BCBSA"), an association of independent health benefit plans.”
Cyber-attack and data security risk
Cost Driver

Cyber-attacks, privacy/data security incidents and failure to modernize information systems or make AI operate as intended are disclosed risks

Relevance 75·Dependency 60·Confidence 90
Source evidence
“the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations”
inflation / medical cost trend
Cost Driver

Public health crises and utilization increases raise medical, hospital and pharmaceutical costs and labor costs, increasing claims liability estimation uncertainty.

Relevance 70·Dependency 60·Confidence 85
Source evidence
“Increased healthcare costs due to higher utilization rates of medical facilities and services and behavioral health services, increased labor costs resulting from labor shortages and increases in medical expenses”
CaremarkPCS Health, L.L.C.
Technology Dependency

Risk disclosure cites non-compliance by any party with the pharmacy services agreement between the company and CaremarkPCS Health

Relevance 70·Dependency 55·Confidence 90
Source evidence
“non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.”
CarelonRx
Revenue Exposure

CarelonRx is a reportable segment providing pharmacy services, a distinct services revenue family alongside Health Benefits.

Relevance 70·Dependency 55·Confidence 90
Source evidence
“Through various subsidiaries, we also offer pharmacy services through our CarelonRx business”
BCBSA license agreements
Regulatory Exposure

BCBSA licenses carry minimum capital/liquidity requirements and could be terminated if business combinations make compliance difficult, threatening a core distribution brand.

Relevance 65·Dependency 70·Confidence 90
Source evidence
“We are also a party to license agreements with the BCBSA which contain additional minimum capital and liquidity requirements.”
interest rates
Cost Driver

Variable rate indebtedness exposes ELV to rising interest rates increasing borrowing costs, alongside investment portfolio interest rate risk.

Relevance 60·Dependency 55·Confidence 90
Source evidence
“We are exposed to interest rate risk to the extent of our variable rate indebtedness. Increases in interest rates could increase our cost of borrowing”
ERISA
Legal Exposure

Potential limitation of ERISA pre-emption and Mental Health Parity Act compliance expose ELV to expanded liability and state regulation of coverage decisions.

Relevance 60·Dependency 55·Confidence 90
Source evidence
“the failure to comply with various state or federal laws, including but not limited to ERISA and the Mental Health Parity Act”
economic downturn / unemployment
Demand Driver

Economic downturns and unemployment from public health crises could reduce enrollment and shift membership mix to less profitable lines of business.

Relevance 55·Dependency 45·Confidence 85
Source evidence
“A reduction in enrollment in our health benefits, pharmacy services, or other healthcare services and products or a change in membership mix to less profitable lines of business by existing customers due to reductions in workforce and other impacts of an economic downturn.”
artificial intelligence
Regulatory Exposure

ELV's use of AI/automation in operations is exposed to emerging AI laws, responsible-AI compliance requirements and ethical/consumer perception risks.

Relevance 55·Dependency 40·Confidence 90
Source evidence
“negative consumer perceptions as to the use of automation and AI, or other complications that could adversely affect our business, reputation, or financial results”
labor shortages / wage growth
Cost Driver

Intense competition for skilled associates may raise salaries, and labor shortages during public health crises increase costs.

Relevance 50·Dependency 45·Confidence 85
Source evidence
“We face intense competition for experienced and highly skilled associates, and we may be unable to attract such associates, or competition among potential associates may result in increasing salaries.”
Full company information
Latest profile, trading, valuation, and identifier data stored for ELV.
Share price
$413.75
Market cap
$89.73B
Exchange
NYSE
Currency
USD
CEO
Gail Koziara Boudreaux
Employees
96,615
IPO date
30/10/2001
Beta
0.711
Last dividend
$0.00
Day range
$411.46 – $416.62
52-week range
$274.84 – $450.69
1-day performance
0.04%
1-year performance
50.54%
Current drawdown (1Y)
-8.20%
CIK
0001156039
CUSIP
036752103
ISIN
US0367521038
Created
07/12/2025, 03:46:06
Last update
03/11/2026, 23:28:59

Track Elevance Health Inc. with an AI analyst

See which prediction-market events move ELV, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to ELV from your Railway `news_articles` table.

Elevance Health: Making The Bull Case For Ongoing Recovery (Rating Upgrade)

Seeking Alpha • STOCK • 01/06/2026, 11:35:33

Elevance Health (ELV) Up 12.6% Since Last Earnings Report: Can It Continue?

Zacks Investment Research • STOCK • 22/05/2026, 14:32:34

Elevance Health, Inc. (ELV) Shareholder/Analyst Call Prepared Remarks Transcript

Seeking Alpha • STOCK • 13/05/2026, 11:50:47

Elevance Health Advances Efforts to Close Critical Gaps in Mental Health Care

Business Wire • STOCK • 04/05/2026, 16:10:00

Elevance Health (NYSE: ELV) Stock Rises on Strong Q1 Earnings and Raised Profit Forecast

Market Data • Market Data • 23/04/2026, 23:17:04

ELV Beats Q1 Earnings Estimates on Rising Net Investment Income

Zacks Investment Research • STOCK • 22/04/2026, 16:11:15

Elevance Health, Inc. (ELV) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 22/04/2026, 16:10:36

Elevance Health (ELV) Surpasses Q1 Earnings and Revenue Estimates

Zacks Investment Research • STOCK • 22/04/2026, 10:16:07

Elevance raises annual profit forecast betting on cost control

Reuters • STOCK • 22/04/2026, 08:06:52

ELEVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Elevance Health, Inc. on Behalf of Elevance Stockholders and Encourages Investors to Contact the Firm

GlobeNewsWire • STOCK • 20/04/2026, 19:06:00

Will Health Benefits Weakness Drag Elevance's Q1 Earnings?

Zacks Investment Research • STOCK • 16/04/2026, 16:35:14

Elevance Health: New Medicare Payment Rate A Gift, And The Chart Looks Good

Seeking Alpha • STOCK • 07/04/2026, 12:32:49